In the liver, AIM is taken up by cells via CD36 where it demonstrates lipolytic activity in normal cells; however, in cancer cells, cellular uptake is suppressed, and AIM accumulates on the cell surface, activating complement proteins and causing subsequent cancer cell death [17]. This evidence concerns the gene VTN and cancer.